The observed potency of DJ4 towards various AML cell lines and primary samples with a diverse set of mutations suggests that this is a promising candidate to be incorporated into the standard AML regimen to help many different subsets of AML patients. This evidence concerns the gene DNAJB6 and acute myeloid leukemia.